Symbols / MCRB
MCRB Chart
About
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 78.25M |
| Enterprise Value | 115.87M | Income | 5.39M | Sales | 351.00K |
| Book/sh | 4.99 | Cash/sh | 5.27 | Dividend Yield | — |
| Payout | 0.00% | Employees | 103 | IPO | — |
| P/E | 9.83 | Forward P/E | -1.09 | PEG | — |
| P/S | 222.94 | P/B | 1.73 | P/C | — |
| EV/EBITDA | -1.17 | EV/Sales | 330.11 | Quick Ratio | 2.16 |
| Current Ratio | 2.30 | Debt/Eq | 195.10 | LT Debt/Eq | — |
| EPS (ttm) | 0.88 | EPS next Y | -7.97 | EPS Growth | -91.90% |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -40.12% |
| ROE | 15.96% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -64.04% | Profit Margin | 15.37% | Shs Outstand | 9.05M |
| Shs Float | 6.75M | Short Float | 14.56% | Short Ratio | 19.16 |
| Short Interest | — | 52W High | 29.98 | 52W Low | 6.53 |
| Beta | 0.25 | Avg Volume | 84.56K | Volume | 58.20K |
| Target Price | $21.00 | Recom | Buy | Prev Close | $8.16 |
| Price | $8.65 | Change | 6.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.00
Mean price target
2. Current target
$8.65
Latest analyst target
3. DCF / Fair value
$-162.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.65
Low
$20.00
High
$22.00
Mean
$21.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-24 | main | Canaccord Genuity | Buy → Buy | $22 |
| 2025-05-08 | down | Chardan Capital | Buy → Neutral | $6 |
| 2025-03-20 | main | Chardan Capital | Buy → Buy | $1 |
| 2025-03-14 | main | Goldman Sachs | Sell → Sell | $1 |
| 2024-11-14 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2024-11-13 | main | Chardan Capital | Buy → Buy | $1 |
| 2024-10-24 | down | JP Morgan | Neutral → Underweight | — |
| 2024-09-13 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2024-08-14 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2024-08-14 | main | Chardan Capital | Buy → Buy | $1 |
| 2024-06-07 | down | Oppenheimer | Outperform → Perform | — |
| 2024-06-07 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2024-05-09 | main | Oppenheimer | Outperform → Outperform | $4 |
| 2024-05-08 | main | Chardan Capital | Buy → Buy | $6 |
| 2024-03-06 | main | Oppenheimer | Outperform → Outperform | $5 |
| 2024-03-06 | main | Chardan Capital | Buy → Buy | $8 |
| 2024-01-16 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2023-11-03 | main | Goldman Sachs | Sell → Sell | $1 |
| 2023-04-28 | main | Chardan Capital | — → Buy | $10 |
| 2023-04-21 | init | JP Morgan | — → Neutral | $7 |
- Understanding the Setup: (MCRB) and Scalable Risk - Stock Traders Daily Sat, 21 Feb 2026 06
- MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits hu, 12 Feb 2026 13
- $MCRB stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- Seres down after pausing investments for lead program - Seeking Alpha hu, 12 Feb 2026 08
- 25% Workforce Cut: Seres Therapeutics Extends Cash Runway While Advancing Breakthrough Blood Infection Drug - Stock Titan ue, 23 Sep 2025 07
- All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy - Yahoo Finance ue, 09 Sep 2025 07
- Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42 - Nasdaq Fri, 05 Dec 2025 08
- individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st Sun, 20 Jul 2025 07
- Seres Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Sun, 30 Nov 2025 06
- Seres stock falls after pausing Phase 2 study and cutting workforce by 30% - Investing.com Nigeria hu, 12 Feb 2026 12
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowstâ„¢ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewswire ue, 06 Jan 2026 08
- Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Fri, 23 May 2025 07
- The Technical Signals Behind (MCRB) That Institutions Follow - Stock Traders Daily ue, 10 Feb 2026 08
- Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more - Seeking Alpha Mon, 08 Sep 2025 07
- Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan ue, 14 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 78 | 661.0 | — | Sale at price 8.47 per share. | DESROSIER THOMAS J | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 1 | 244 | nan | — | — | DESROSIER THOMAS J | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 259 | 2194.0 | — | Sale at price 8.47 per share. | SHAFF ERIC D | Director | — | 2026-02-13 00:00:00 | D |
| 3 | 723 | nan | — | — | SHAFF ERIC D | Director | — | 2026-02-13 00:00:00 | D |
| 4 | 89 | 754.0 | — | Sale at price 8.47 per share. | HENN MATTHEW R | Officer | — | 2026-02-13 00:00:00 | D |
| 5 | 239 | nan | — | — | HENN MATTHEW R | Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 75 | 635.0 | — | Sale at price 8.47 per share. | YOUNG TERESA L. | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 231 | nan | — | — | YOUNG TERESA L. | Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 76 | 1315.0 | — | Sale at price 17.30 per share. | DESROSIER THOMAS J | Chief Executive Officer | — | 2025-11-14 00:00:00 | D |
| 9 | 244 | nan | — | — | DESROSIER THOMAS J | Chief Executive Officer | — | 2025-11-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -125.99M | -181.42M | -170.93M | -56.72M |
| TotalUnusualItems | 5.68M | 0.00 | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 5.68M | 0.00 | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -125.77M | -190.13M | -183.58M | -65.58M |
| ReconciledDepreciation | 5.47M | 6.24M | 6.63M | 5.95M |
| ReconciledCostOfRevenue | 3.53M | 0.00 | 0.00 | |
| EBITDA | -120.30M | -181.42M | -170.93M | -56.72M |
| EBIT | -125.77M | -187.66M | -177.56M | -62.67M |
| NetInterestIncome | 3.97M | 4.83M | -2.96M | -40.00K |
| InterestExpense | 0.00 | 2.47M | 6.02M | 2.91M |
| InterestIncome | 3.97M | 7.30M | 3.06M | 2.87M |
| NormalizedIncome | -131.46M | -190.13M | -183.58M | -65.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 136.00K | -113.72M | -250.16M | -65.58M |
| TotalExpenses | 121.31M | 195.10M | 179.91M | 209.42M |
| TotalOperatingIncomeAsReported | -121.31M | -195.10M | -179.91M | -64.49M |
| DilutedAverageShares | 7.77M | 6.40M | 5.40M | 4.59M |
| BasicAverageShares | 7.77M | 6.40M | 5.40M | 4.59M |
| DilutedEPS | 0.00 | -17.80 | -46.20 | -14.40 |
| BasicEPS | 0.00 | -17.80 | -46.20 | -14.40 |
| DilutedNIAvailtoComStockholders | 136.00K | -113.72M | -250.16M | -65.58M |
| NetIncomeCommonStockholders | 136.00K | -113.72M | -250.16M | -65.58M |
| NetIncome | 136.00K | -113.72M | -250.16M | -65.58M |
| NetIncomeIncludingNoncontrollingInterests | 136.00K | -113.72M | -250.16M | -65.58M |
| NetIncomeDiscontinuousOperations | 125.91M | 76.41M | -66.58M | |
| NetIncomeContinuousOperations | -125.77M | -190.13M | -183.58M | -65.58M |
| PretaxIncome | -125.77M | -190.13M | -183.58M | -65.58M |
| OtherIncomeExpense | -8.42M | 134.00K | -705.00K | -1.04M |
| OtherNonOperatingIncomeExpenses | -14.11M | 134.00K | -705.00K | -1.04M |
| SpecialIncomeCharges | 5.68M | 0.00 | 0.00 | 0.00 |
| GainOnSaleOfBusiness | 5.68M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 3.97M | 4.83M | -2.96M | -40.00K |
| InterestExpenseNonOperating | 0.00 | 2.47M | 6.02M | 2.91M |
| InterestIncomeNonOperating | 3.97M | 7.30M | 3.06M | 2.87M |
| OperatingIncome | -121.31M | -195.10M | -179.91M | -64.49M |
| OperatingExpense | 117.78M | 195.10M | 179.91M | 209.42M |
| OtherOperatingExpenses | 704.00K | 1.00M | -1.73M | |
| ResearchAndDevelopment | 64.60M | 117.60M | 109.65M | 141.89M |
| SellingGeneralAndAdministration | 53.18M | 77.50M | 70.26M | 69.26M |
| GeneralAndAdministrativeExpense | 53.18M | 77.50M | 70.26M | 69.26M |
| OtherGandA | 30.50M | 41.43M | 70.26M | 69.26M |
| SalariesAndWages | 22.68M | 36.07M | 31.28M | 23.93M |
| GrossProfit | -3.53M | 0.00 | 0.00 | |
| CostOfRevenue | 3.53M | 0.00 | 0.00 | |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 144.93M |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 144.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.65M | 6.75M | 6.26M | 4.59M |
| ShareIssued | 8.65M | 6.75M | 6.26M | 4.59M |
| TotalDebt | 91.64M | 198.78M | 162.59M | 49.21M |
| TangibleBookValue | 13.78M | -44.86M | 10.78M | 131.51M |
| InvestedCapital | 13.78M | 56.69M | 61.83M | 156.15M |
| WorkingCapital | -2.55M | 76.75M | 109.17M | 221.37M |
| NetTangibleAssets | 13.78M | -44.86M | 10.78M | 131.51M |
| CapitalLeaseObligations | 91.64M | 97.24M | 111.54M | 24.57M |
| CommonStockEquity | 13.78M | -44.86M | 10.78M | 131.51M |
| TotalCapitalization | 13.78M | 56.69M | 61.37M | 156.15M |
| TotalEquityGrossMinorityInterest | 13.78M | -44.86M | 10.78M | 131.51M |
| StockholdersEquity | 13.78M | -44.86M | 10.78M | 131.51M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -12.00K | -60.00K | |
| OtherEquityAdjustments | -12.00K | -60.00K | ||
| RetainedEarnings | -978.10M | -978.24M | -864.51M | -614.35M |
| AdditionalPaidInCapital | 991.71M | 933.24M | 875.18M | 745.83M |
| CapitalStock | 173.00K | 135.00K | 125.00K | 92.00K |
| CommonStock | 173.00K | 135.00K | 125.00K | 92.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 126.03M | 403.46M | 338.00M | 223.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 84.80M | 304.80M | 252.41M | 141.09M |
| OtherNonCurrentLiabilities | 1.84M | 1.63M | 1.44M | 11.49M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 109.43M | ||
| DerivativeProductLiabilities | 0.00 | 546.00K | 0.00 | |
| NonCurrentDeferredLiabilities | 95.36M | 92.43M | 87.00M | |
| NonCurrentDeferredRevenue | 95.36M | 92.43M | 87.00M | |
| LongTermDebtAndCapitalLeaseObligation | 82.97M | 193.20M | 158.53M | 42.60M |
| LongTermCapitalLeaseObligation | 82.97M | 91.65M | 107.94M | 17.96M |
| LongTermDebt | 101.54M | 50.59M | 24.64M | |
| CurrentLiabilities | 41.22M | 98.66M | 85.60M | 82.26M |
| OtherCurrentLiabilities | 66.92M | 34.77M | 21.10M | |
| CurrentDeferredLiabilities | 7.73M | 4.26M | 16.82M | |
| CurrentDeferredRevenue | 7.73M | 4.26M | 16.82M | |
| CurrentDebtAndCapitalLeaseObligation | 8.67M | 5.59M | 4.06M | 6.61M |
| CurrentCapitalLeaseObligation | 8.67M | 5.59M | 3.60M | 6.61M |
| CurrentDebt | 456.00K | |||
| OtherCurrentBorrowings | 456.00K | |||
| PayablesAndAccruedExpenses | 32.55M | 26.15M | 77.28M | 37.73M |
| CurrentAccruedExpenses | 28.47M | 22.51M | 25.07M | 24.00M |
| Payables | 4.08M | 3.64M | 52.21M | 13.73M |
| DuetoRelatedPartiesCurrent | 28.05M | 34.77M | ||
| AccountsPayable | 4.08M | 3.64M | 17.44M | 13.73M |
| TotalAssets | 139.81M | 358.60M | 348.78M | 354.86M |
| TotalNonCurrentAssets | 101.14M | 183.19M | 154.02M | 51.23M |
| OtherNonCurrentAssets | 8.70M | 75.16M | 20.05M | 14.59M |
| InvestmentsAndAdvances | 0.00 | 495.00K | ||
| InvestmentinFinancialAssets | 0.00 | 495.00K | ||
| AvailableForSaleSecurities | 495.00K | |||
| NetPPE | 92.44M | 108.03M | 133.97M | 36.15M |
| AccumulatedDepreciation | -53.20M | -49.08M | -45.04M | -40.27M |
| GrossPPE | 145.63M | 157.11M | 179.01M | 76.41M |
| Leases | 30.95M | 32.49M | 32.47M | 32.92M |
| ConstructionInProgress | 861.00K | 1.11M | 3.97M | 1.67M |
| OtherProperties | 105.37M | 115.08M | 135.52M | 37.34M |
| MachineryFurnitureEquipment | 8.45M | 8.42M | 7.05M | 4.47M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 38.67M | 175.41M | 194.76M | 303.63M |
| OtherCurrentAssets | 3.13M | 8.05M | 13.42M | 12.92M |
| AssetsHeldForSaleCurrent | 0.00 | 39.40M | ||
| PrepaidAssets | 12.92M | |||
| Inventory | 29.65M | 0.00 | ||
| FinishedGoods | 0.00 | 0.00 | ||
| WorkInProcess | 25.22M | 0.00 | ||
| RawMaterials | 4.43M | 0.00 | ||
| Receivables | 4.75M | 0.00 | 0.00 | 0.00 |
| OtherReceivables | 2.68M | |||
| DuefromRelatedPartiesCurrent | 8.67M | 0.00 | ||
| AccountsReceivable | 2.07M | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 30.79M | 127.97M | 181.34M | 290.71M |
| OtherShortTermInvestments | 0.00 | 18.31M | 110.70M | |
| CashAndCashEquivalents | 30.79M | 127.97M | 163.03M | 180.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -148.99M | -125.33M | -238.64M | -2.88M |
| RepaymentOfDebt | -127.91M | -52.86M | -1.91M | -948.00K |
| IssuanceOfDebt | 0.00 | 103.38M | 27.61M | 0.00 |
| IssuanceOfCapitalStock | 23.53M | 18.16M | 101.17M | 0.00 |
| CapitalExpenditure | -380.00K | -7.97M | -9.82M | -9.57M |
| InterestPaidSupplementalData | 10.86M | 12.55M | 4.93M | 2.45M |
| EndCashPosition | 39.46M | 136.15M | 171.22M | 188.00M |
| BeginningCashPosition | 136.15M | 171.22M | 188.00M | 116.05M |
| EffectOfExchangeRateChanges | -1.00K | 2.00K | -1.00K | -1.00K |
| ChangesInCash | -96.69M | -35.07M | -16.79M | 71.95M |
| FinancingCashFlow | -90.37M | 71.70M | 129.60M | 1.18M |
| CashFlowFromContinuingFinancingActivities | -90.37M | 71.70M | 129.60M | 1.18M |
| NetOtherFinancingCharges | 13.52M | |||
| ProceedsFromStockOptionExercised | 487.00K | 3.03M | 2.73M | 2.13M |
| NetCommonStockIssuance | 23.53M | 18.16M | 101.17M | 0.00 |
| CommonStockIssuance | 23.53M | 18.16M | 101.17M | 0.00 |
| NetIssuancePaymentsOfDebt | -127.91M | 50.52M | 25.70M | -948.00K |
| NetLongTermDebtIssuance | -127.91M | 50.52M | 25.70M | -948.00K |
| LongTermDebtPayments | -127.91M | -52.86M | -1.91M | -948.00K |
| LongTermDebtIssuance | 0.00 | 103.38M | 27.61M | 0.00 |
| InvestingCashFlow | 142.29M | 10.58M | 82.43M | 64.09M |
| CashFlowFromContinuingInvestingActivities | 142.29M | 10.58M | 82.43M | 64.09M |
| NetOtherInvestingChanges | 1.40M | |||
| NetInvestmentPurchaseAndSale | 0.00 | 18.56M | 92.25M | 73.65M |
| SaleOfInvestment | 0.00 | 22.98M | 140.47M | 169.62M |
| PurchaseOfInvestment | 0.00 | -4.43M | -48.22M | -95.97M |
| NetBusinessPurchaseAndSale | 141.27M | 0.00 | 0.00 | |
| SaleOfBusiness | 141.27M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -380.00K | -7.97M | -9.82M | -9.57M |
| PurchaseOfPPE | -380.00K | -7.97M | -9.82M | -9.57M |
| OperatingCashFlow | -148.61M | -117.35M | -228.82M | 6.69M |
| CashFlowFromContinuingOperatingActivities | -148.61M | -117.35M | -228.82M | 6.69M |
| ChangeInWorkingCapital | -65.51M | -58.98M | -18.39M | 41.53M |
| ChangeInOtherWorkingCapital | -4.12M | 6.41M | -7.13M | -4.36M |
| ChangeInOtherCurrentLiabilities | -6.34M | -2.20M | -4.20M | -3.55M |
| ChangeInPayablesAndAccruedExpense | -28.84M | 4.26M | 5.54M | 52.39M |
| ChangeInAccruedExpense | -25.90M | 15.84M | 3.34M | 43.02M |
| ChangeInPayable | -2.94M | -11.58M | 2.20M | 9.36M |
| ChangeInAccountPayable | -2.94M | -11.58M | 2.20M | 9.36M |
| ChangeInPrepaidAssets | 987.00K | -29.12M | -12.60M | -12.34M |
| ChangeInInventory | -33.80M | -29.65M | 0.00 | 0.00 |
| ChangeInReceivables | 6.61M | -8.67M | 0.00 | 9.39M |
| ChangesInAccountReceivables | -2.07M | 0.00 | 0.00 | 9.39M |
| OtherNonCashItems | 10.64M | 15.17M | 6.93M | 4.07M |
| StockBasedCompensation | 20.97M | 34.10M | 25.48M | 20.22M |
| AssetImpairmentCharge | 3.27M | 0.00 | 0.00 | |
| AmortizationOfSecurities | 0.00 | -236.00K | 688.00K | 498.00K |
| DepreciationAmortizationDepletion | 5.47M | 6.24M | 6.63M | 5.95M |
| DepreciationAndAmortization | 5.47M | 6.24M | 6.63M | 5.95M |
| Depreciation | 5.47M | 6.24M | 6.63M | |
| OperatingGainsLosses | -123.58M | 71.00K | ||
| GainLossOnInvestmentSecurities | -546.00K | -1.55M | ||
| GainLossOnSaleOfPPE | 317.00K | 0.00 | 0.00 | 0.00 |
| GainLossOnSaleOfBusiness | -146.71M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 136.00K | -113.72M | -250.16M | -65.58M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MCRB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|